Witryna8 wrz 2024 · The trial, IMpassion131, was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of atezolizumab in combination with paclitaxel compared with placebo and paclitaxel for... Witryna10 paź 2024 · IMpassion131 Design The double-blind, placebo-controlled phase III trial enrolled 651 patients with metastatic or unresectable locally advanced triple-negative breast cancer and no prior chemotherapy or targeted therapy for advanced disease. PD-L1 positivity (≥ 1%) was documented in 291 patients.

ESMO Virtual Congress 2024 OncologyPRO

Witryna27 lis 2024 · The IMpassion130 trial is a randomised, double-blind, placebo-controlled trial that was done in 246 academic centres and community oncology practices in 41 … WitrynaEmpassion Pelvic Health was founded by PTs with a goal to change the face of pelvic floor, women’s, and men’s health services across the lifespan. We focus on holistic, … rayhom battery review

HealthImpression - trening EMS

WitrynaIMpassion031 is a global, Ph 3, multicentre, double-blind, randomised, placebo-controlled study in pts with high-risk primary invasive eTNBC evaluating the efficacy and safety of neoadj atezolizumab (A) or placebo (P) with nab-paclitaxel (nP) followed by A or P with dose-dense doxorubicin + cyclophosphamide. WitrynaBased on findings from IMpassion130, international guidelines now recommend atezolizumab (A) + nab-paclitaxel (nP) for patients (pts) with locally advanced or metastatic TNBC (mTNBC) whose tumours express PD-L1 on tumour-infiltrating immune cells (IC). Here we report prespecified final OS and long-term safety results. Methods WitrynaBackground. Preferred neoadj regimens for patients (pts) with early-stage (e)TNBC include taxane + anthracycline–based therapy. IMpassion031 is a global, phase III, multicentre, double-blind, randomised, placebo-controlled study in pts with high-risk primary invasive eTNBC evaluating the efficacy and safety of neoadj atezolizumab (A) … simple tuscan living room